Elling v. Mesa Biotech, Inc.

CourtDistrict Court, D. New Mexico
DecidedJune 17, 2020
Docket1:19-cv-00547
StatusUnknown

This text of Elling v. Mesa Biotech, Inc. (Elling v. Mesa Biotech, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. New Mexico primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Elling v. Mesa Biotech, Inc., (D.N.M. 2020).

Opinion

IN THE UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF NEW MEXICO

JOHN ELLING,

Plaintiff, v. 1:19-cv-00547-LF-SCY

MESA BIOTECH, INC., MESA TECH INTERNATIONAL, INC., HONG CAI, and ROBERT BRUCE CARY, a/k/a R. BRUCE CARY, a/k/a ROBERT CARY,

Defendants.

MEMORANDUM OPINION AND ORDER DENYING PLAINTIFF’S AMENDED MOTION FOR VOLUNTARY DISMISSAL BY ORDER OF COURT OR, ALTERNATIVELY, TO CONSOLIDATE

THIS MATTER comes before the Court on Plaintiff John Elling’s Amended Motion for Voluntary Dismissal by Order of Court or, Alternatively, to Consolidate, filed April 14, 2020. Doc. 54. Defendants Mesa Biotech, Inc., Mesa Tech International, Inc. (“MTI”), Hong Cai, and Robert Bruce Cary filed their response in opposition to the motion on April 28, 2020, and Mr. Elling filed his reply on May 12, 2020. Docs. 56, 57. The parties consented to my conducting dispositive proceedings in this matter. See Docs. 6, 7, 9. For the following reasons, the Court DENIES Mr. Elling’s motion. I. Factual and Procedural Background This case arises out of a dispute between Plaintiff John Elling, formerly Director, President, and Chief Executive Officer of MTI, and his former colleagues, Defendants Hong Cai and Robert Bruce Cary, who now are employed at Defendant Mesa Biotech. See Doc. 1-1 (complaint) ¶¶ 6−10, 20−34; Doc. 3 (answer) ¶¶ 6–10, 20–34. Mr. Elling founded MTI with Ms. Cai and Mr. Cary, and all three were initial shareholders. Doc. 1-1 ¶¶ 2−4; Doc. 3 ¶¶ 2–4. MTI was a New Mexico Corporation with its principal place of business in Los Alamos County, New Mexico. See Doc. 1-1 ¶ 5; Doc. 3 ¶ 5. In October 2010, Mr. Elling agreed to resign from his positions at MTI, but he retained a portion of MTI’s stock pursuant to a written agreement. Doc.

1-1 ¶ 20; Doc. 3 ¶ 20; see also Doc. 1-1 at 10−12 (agreement between MTI and Mr. Elling). In July 2015, MTI merged with Mesa Biotech. Doc. 1-4 at 5. By virtue of the merger, MTI was subsumed by Mesa Biotech, MTI ceased to exist, and Mr. Elling became a minority shareholder in Mesa Biotech. See Doc. 1-2 at 1–2; Doc. 1-4 at 5; Doc. 43-1 at 11. Mr. Elling claims that he first learned of MTI’s merger with Mesa Biotech in August 2018. Doc. 1-1 ¶¶ 23– 25. In October 2018 and January 2019, Mr. Elling sought to inspect MTI and Mesa Biotech’s books and records, allegedly without success. Doc. 1-1 ¶¶ 31–34. On May 7, 2019, Mr. Elling filed his complaint in this case in the First Judicial District Court of New Mexico. Doc. 1-1. Defendants removed the case to this Court on June 13, 2019. Doc. 1. In July 2019, Mr. Elling sought to remand the case back to state court, Doc. 8, which the

Court denied in October 2019, Doc. 30. On August 6, 2019, the Court issued a scheduling order that set a deadline of February 7, 2020 to complete all discovery, and a deadline of March 9, 2020 for all dispositive motions to be filed. Doc. 17. During discovery, the parties disagreed about the precise terms of a confidentiality order under which certain discovery would be provided, and the Court ultimately resolved those issues on December 4, 2019. Docs. 25, 26, 28, 29, 31, 32. Once the confidentiality order was in place, Mr. Elling received access to Mesa Biotech’s books and records as part of the discovery in this case. Doc. 49 at 7, ¶ 18. But Mr. Elling never sought any adjustment of any of the deadlines contained in the Court’s scheduling order, nor did he ever seek to amend his complaint. See generally Docket, Case. No. 1:19-cv- 00547-LF-SCY. On March 9, 2020, Defendants timely filed their motion for summary judgment, seeking a final judgment in their favor on all Mr. Elling’s claims. Doc. 43. The briefing on this motion

was complete on April 8, 2020. See Doc. 51. Five days earlier, on April 3, 2020, Mr. Elling filed another lawsuit against Ms. Cai, Mr. Cary, Mesa Biotech, and MTI. See Doc. 1, Case No. 1:20-cv-00306-JHR-JFR. Mr. Elling filed an amended complaint in that case on April 7, 2020 and served the defendants with the amended complaint on April 15 and 16, 2020. Docs. 3, 5–8, Case No. 1:20-cv-00306-JHR-JFR. On April 14, 2020, Mr. Elling filed his Motion and Amended Motion for Voluntary Dismissal by Order of Court or, Alternatively, to Consolidate. Docs. 53, 54. II. Mr. Elling’s Complaints In this case, Mr. Elling alleges that over the years, he received scant information regarding MTI’s operations. Doc. 1-1 ¶ 22. He claims that he first learned that MTI had merged

with Mesa Biotech, Inc. in August 2018. Id. ¶¶ 23, 24. According to the complaint, Mr. Elling received no notice of any proposed merger or proposed amendment to MTI’s articles of incorporation, nor did he receive the opportunity to vote on the proposed merger, nor was a merger plan submitted to MTI’s shareholders. Id. ¶¶ 25−27. Mr. Elling also alleges that MTI/Mesa Biotech refused to allow him to inspect their books and records and refused to address his concerns regarding the merger, amendments to the company’s articles of incorporation and bylaws, the company’s relocation to California, and changes to its stock plan. Id. ¶ 29−34. In count I of his complaint, Mr. Elling claims that Ms. Cai and Mr. Cary breached their fiduciary duties to him. Id. ¶¶ 35−38. Count II alleges that Defendants collectively engaged in “shareholder oppression.” Id. ¶¶ 39−41. Count III alleges that MTI breached its contract with Mr. Elling, including breaching the covenant of good faith and fair dealing. Id. ¶¶ 42−46. Mr. Elling seeks compensatory, punitive, and statutory damages, as well as his attorneys’ fees and costs. Id. at 8.

In Mr. Elling’s new complaint, he alleges new facts regarding “2014 Interested Transaction”—before MTI’s merger with Mesa Biotech—and “2018 Interested Transactions.” Doc. 3 ¶¶ 28–37, 41–52, Case No. 1:20-cv-00306-JHR-JFR. Count I of the complaint alleges that Ms. Cai and Mr. Cary breached their fiduciary duties to Mr. Elling multiple times, and Count II alleges that they aided and abetted each other in breaching these duties. Id. ¶¶ 53–71. Count III alleges that all Defendants engaged in shareholder oppression. Id. ¶¶ 72–74. Mr. Elling seeks compensatory and punitive damages, pre- and post-judgment interest, attorneys’ fees and costs, and asks the Court to rescind the “options and cancel the shares Cai & Cary gave themselves at the expense of the Company.” Id. at 8, ¶¶ A–E. III. Mr. Elling’s Motion and Defendants’ Response

Mr. Elling argues that the Court should dismiss this case because his “new case against Defendants seek[s] redress for the substantive matter of Cai & Cary’s interested transactions,” and his damages from those “transactions are significantly greater than his damages resulting from the merger or books and records issues.” Doc. 54 ¶¶ 12, 13. He states that he “is not seeking a remedy for the merger or books and records issues in the other case,” and that he “desires to focus his time and financial resources on his substantive claims resulting from the interested transactions.” Id. ¶¶ 14, 17. He asserts that “[i]t is not a good use of the Parties’ or the Court’s resources to continue litigation of the merger or books and records issues given the more impactful nature of the claims for the interested transactions and the limited resources of the Parties and the Court.” Id. ¶ 18. If the Court chooses not to dismiss the case, Mr. Elling says the cases should be consolidated because “[t]he Parties are the same in both cases”; “[b]oth cases involve the common legal issue of Defendant Cai and Cary’s fiduciary obligations to Plaintiff as a minority shareholder,” and that if the Court were to consolidate the cases, Mr. Elling would

like a new scheduling order resetting all the discovery deadlines and the deadlines for filing pretrial motions. Id. ¶¶ 15, 16, 19. He also notes that there is no trial setting in this case. Id. ¶ 21. Defendants argue that the Court should deny Mr. Elling’s motion.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Elling v. Mesa Biotech, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/elling-v-mesa-biotech-inc-nmd-2020.